News By Tag
News By Place
New Technologies in Type 1 and Type 2 Diabetes Management
As well established as the practices are for the management of types 1 and 2 diabetes, a raft of new technologies, from modest to radical, are steadily entering clinical practice and the industry, according to a new report from MedMarket Diligence.
“Without a doubt, the 10-year study known as Diabetes Control and Complications Trial, or DCCT, played an enormous role in validating the technologies that now routinely serve to improve the quality of life for diabetics,” says Patrick Driscoll, President of the medical technology business research firm MedMarket Diligence. “But the steady growth in diabetes prevalence worldwide, driven by increased prevalence of obesity, demographic trends and other forces, combined with persistent demand for ever less intrusive monitoring technologies and better long-term blood glucose management, creates an enormous opportunity for new technology development by diabetes product manufacturers.”
According to Driscoll, and detailed in the MedMarket Diligence report (see http://www.mediligence.com/
Growth in the market for diabetes management products ranges globally from a low of about 11% annually in Europe to nearly 24% annually in Asia. Overall, the U.S. and Europe, with their advanced healthcare markets and payment systems, still represent an aggregate 68% of the global market. By product area, the segments driving the largest annual revenues are insulins and anti-diabetic drugs, comprising almost two thirds of the global sales of diabetes management products.
The MedMarket Diligence report #D510, “Products, Technologies, Markets and Opportunities in Diabetes Management Worldwide, 2009-2018,” details the worldwide incidence and prevalence by country/region of Type 1 and Type 2 diabetes and details the current and projected market for diagnostic and therapeutic products in the management of diabetes, including anti-diabetic drugs, alternative insulin types, blood glucose monitoring (including continuous monitoring devices), insulin pumps, and other established and emerging products in diabetes management. The report provides an emphasis of detail on the status of development of novel products including noninvasive monitoring, oral/inhaled/
The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.
The report is described, with complete table of contents and list of exhibits at http://www.mediligence.com/
# # #
MedMarket Diligence provides data and insight to the medical products, investment and other industries on advanced medical technologies through focused medical technology market and assessment Reports and the Medtech Startups Database.